27 November 2024 - Wegovy is the first and only medication indicated for both chronic weight management and to reduce the risk of non-fatal myocardial infarction in Canada.

Novo Nordisk announced today that Wegovy (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and a body mass index equal to or greater than 27 kg/m2.

Read Novo Nordisk press release